Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Lineage Cell Therapeutics

DB:BT3
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BT3
DB
$149M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
BT3 Share Price and Events
7 Day Returns
0%
DB:BT3
0%
DE Biotechs
0.8%
DE Market
1 Year Returns
-58.4%
DB:BT3
-5.6%
DE Biotechs
-10.9%
DE Market
BT3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Lineage Cell Therapeutics (BT3) 0% -15.1% -5.4% -58.4% -66% -60.3%
DE Biotechs 0% -2% 5.2% -5.6% 91.5% 21.9%
DE Market 0.8% -5.9% -2.9% -10.9% 0.9% 8%
1 Year Return vs Industry and Market
  • BT3 underperformed the Biotechs industry which returned -5.6% over the past year.
  • BT3 underperformed the Market in Germany which returned -10.9% over the past year.
Price Volatility
BT3
Industry
5yr Volatility vs Market

Value

 Is Lineage Cell Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Lineage Cell Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.8821.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Lineage Cell Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Lineage Cell Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BT3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $0.23
AMEX:LCTX Share Price ** AMEX (2019-08-09) in USD $0.99
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 29.21x
Germany Market PE Ratio Median Figure of 413 Publicly-Listed Companies 18.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Lineage Cell Therapeutics.

DB:BT3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:LCTX Share Price ÷ EPS (both in USD)

= 0.99 ÷ 0.23

4.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lineage Cell Therapeutics is good value based on earnings compared to the Europe Biotechs industry average.
  • Lineage Cell Therapeutics is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Lineage Cell Therapeutics's expected growth come at a high price?
Raw Data
DB:BT3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 4.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-36.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 0.87x
Germany Market PEG Ratio Median Figure of 265 Publicly-Listed Companies 1.33x

*Line of best fit is calculated by linear regression .

DB:BT3 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 4.29x ÷ -36.6%

-0.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lineage Cell Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Lineage Cell Therapeutics's assets?
Raw Data
DB:BT3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $0.89
AMEX:LCTX Share Price * AMEX (2019-08-09) in USD $0.99
Germany Biotechs Industry PB Ratio Median Figure of 13 Publicly-Listed Biotechs Companies 3.07x
Germany Market PB Ratio Median Figure of 569 Publicly-Listed Companies 1.64x
DB:BT3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:LCTX Share Price ÷ Book Value per Share (both in USD)

= 0.99 ÷ 0.89

1.11x

* Primary Listing of Lineage Cell Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Lineage Cell Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Lineage Cell Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Lineage Cell Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Lineage Cell Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-36.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Lineage Cell Therapeutics expected to grow at an attractive rate?
  • Lineage Cell Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Lineage Cell Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Lineage Cell Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BT3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BT3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -36.6%
DB:BT3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 65.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.1%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 33.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BT3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BT3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 46 -70 3
2022-12-31 12 -49 3
2021-12-31 8 -47 3
2020-12-31 4 -44 4
2019-12-31 3 -10 4
DB:BT3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 3 -32 31
2019-03-31 5 -30 57
2018-12-31 5 -31 -46
2018-09-30 5 -31 -73
2018-06-30 6 -31 -125
2018-03-31 4 -33 -133
2017-12-31 3 -31 -20
2017-09-30 4 -34 47
2017-06-30 3 -35 64
2017-03-31 4 -36 100
2016-12-31 6 -42 34
2016-09-30 6 -47 25

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Lineage Cell Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Lineage Cell Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BT3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Lineage Cell Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BT3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.35 -0.23 -0.46 2.00
2022-12-31 -0.25 -0.12 -0.45 3.00
2021-12-31 -0.26 -0.14 -0.41 3.00
2020-12-31 -0.26 -0.16 -0.36 4.00
2019-12-31 -0.05 0.00 -0.10 4.00
DB:BT3 Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 0.23
2019-03-31 0.44
2018-12-31 -0.36
2018-09-30 -0.58
2018-06-30 -1.02
2018-03-31 -1.11
2017-12-31 -0.17
2017-09-30 0.43
2017-06-30 0.60
2017-03-31 0.99
2016-12-31 0.34
2016-09-30 0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Lineage Cell Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Lineage Cell Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Lineage Cell Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Lineage Cell Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Lineage Cell Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Lineage Cell Therapeutics's year on year earnings growth rate has been positive over the past 5 years.
  • Lineage Cell Therapeutics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • Lineage Cell Therapeutics has become profitable in the last year making it difficult to compare the Europe Biotechs industry average.
Earnings and Revenue History
Lineage Cell Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Lineage Cell Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BT3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 3.45 31.05 24.08 18.86
2019-03-31 5.22 56.87 23.84 19.98
2018-12-31 4.99 -45.99 24.73 20.96
2018-09-30 5.23 -72.97 23.40 21.87
2018-06-30 5.93 -125.38 21.56 23.55
2018-03-31 3.77 -132.81 20.87 23.47
2017-12-31 3.46 -19.98 19.92 24.02
2017-09-30 3.54 46.88 19.45 26.34
2017-06-30 3.35 63.77 19.44 26.20
2017-03-31 4.24 99.97 21.66 28.87
2016-12-31 5.92 33.57 28.43 36.11
2016-09-30 6.30 25.22 33.31 41.88
2016-06-30 7.11 -20.05 36.28 46.89
2016-03-31 7.85 -54.35 35.83 47.02
2015-12-31 7.04 -47.41 29.13 42.60
2015-09-30 7.45 -44.62 23.70 41.08
2015-06-30 6.34 -38.77 20.42 38.45
2015-03-31 5.44 -38.57 19.07 38.45
2014-12-31 5.24 -36.50 17.56 37.53
2014-09-30 5.26 -45.47 17.05 35.49
2014-06-30 4.78 -46.24 17.06 33.10
2014-03-31 4.89 -44.26 15.81 29.62
2013-12-31 4.43 -43.88 15.56 26.61
2013-09-30 3.76 -30.31 14.60 22.18
2013-06-30 4.05 -26.28 12.57 20.32
2013-03-31 3.88 -24.17 11.41 19.33
2012-12-31 3.92 -21.43 10.37 18.12
2012-09-30 4.34 -20.75 10.19 17.27

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Lineage Cell Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Lineage Cell Therapeutics used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Lineage Cell Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Lineage Cell Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Lineage Cell Therapeutics has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Lineage Cell Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Lineage Cell Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Lineage Cell Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Lineage Cell Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Lineage Cell Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -2.3034786194093E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Lineage Cell Therapeutics Company Filings, last reported 1 month ago.

DB:BT3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 131.76 0.00 16.69
2019-03-31 161.24 0.02 27.10
2018-12-31 92.25 0.07 30.74
2018-09-30 169.56 0.07 21.44
2018-06-30 104.75 0.12 29.16
2018-03-31 102.46 0.12 31.38
2017-12-31 164.26 0.17 38.18
2017-09-30 208.99 0.18 18.17
2017-06-30 178.19 2.77 15.77
2017-03-31 189.70 2.37 24.73
2016-12-31 130.51 2.08 22.72
2016-09-30 136.24 1.58 31.35
2016-06-30 94.05 0.97 28.32
2016-03-31 59.59 0.71 27.96
2015-12-31 76.45 0.64 42.98
2015-09-30 60.93 0.62 29.38
2015-06-30 64.95 0.24 31.47
2015-03-31 57.51 0.17 25.83
2014-12-31 62.72 0.06 29.49
2014-09-30 38.95 0.00 7.42
2014-06-30 46.58 0.00 15.72
2014-03-31 45.36 0.00 6.64
2013-12-31 42.26 0.00 5.50
2013-09-30 25.37 0.00 6.72
2013-06-30 34.52 0.00 14.31
2013-03-31 29.98 0.00 9.90
2012-12-31 24.29 0.00 4.35
2012-09-30 29.21 0.00 7.83
  • Lineage Cell Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
  • Debt is well covered by operating cash flow (3.6169534507319E+18%, greater than 20% of total debt).
  • Lineage Cell Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Lineage Cell Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Lineage Cell Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Lineage Cell Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Lineage Cell Therapeutics dividends.
If you bought €2,000 of Lineage Cell Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Lineage Cell Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Lineage Cell Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BT3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 321 Stocks 3.3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BT3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Lineage Cell Therapeutics has not reported any payouts.
  • Unable to verify if Lineage Cell Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Lineage Cell Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Lineage Cell Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Lineage Cell Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Lineage Cell Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Lineage Cell Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Lineage Cell Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brian Culley
COMPENSATION $3,159,531
AGE 48
TENURE AS CEO 0.9 years
CEO Bio

Mr. Brian M. Culley, M.A., M.B.A., has been President, Chief Executive Officer and Director of BioTime, Inc. since September 17, 2018. Mr. Culley served as Chief Executive Officer of Artemis Therapeutics Inc. from August 9, 2017 to August 10, 2018. Mr. Culley served as the Chief Executive Officer of Mast Therapeutics, Inc. since February 2010 until April 2017. He served as Chief Executive Officer of Savara Inc. He served as the Chief Business Officer and Senior Vice President at Adventrx Pharmaceuticals Inc. /Mast Therapeutics, Inc. from January 2007 to February 2010 and served as its Principal Executive Officer since February 2009, it is Senior Vice President of Business Development from February 2006 to January 2007 and its Vice President of Business Development from December 2004 to February 2006. He joined Adventrx Pharmaceuticals in December 2004. He served as the Interim Principal Executive Officer at Adventrx Pharmaceuticals Inc. since February 3, 2009. He served as a Vice President of Business Development of Adventrx Pharmaceuticals Inc. from December 2004 to February 2006. From 2002 to 2004, Mr. Culley managed all strategic collaborations and licensing agreements for iTherx, Inc. (formerly, Immusol, Inc.) in San Diego. He served as Director of Business Development & Marketing for Immusol, Inc., a privately-held drug development company in San Diego from 2002 to 2004. From 1999 to 2000, he served as a Licensing & Marketing Associate at the University of California, San Diego Department of Technology Transfer & Intellectual Property Services and from 1996 to 1999, he served as a Research Associate for Neurocrine Biosciences Inc., where he performed drug discovery research. Mr. Culley has 25 years of business and scientific experience in the life science industry. Mr. Culley served as a Director of Mast Therapeutics, Inc. since December 8, 2011 until April 2017. He received a BS in biology from Boston College, an M.S. in biochemistry and molecular biology from the University of California, Santa Barbara and an MBA from The Johnson School of Business at Cornell University with an emphasis on private equity and entrepreneurship.

CEO Compensation
  • Insufficient data for Brian to compare compensation growth.
  • Brian's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Lineage Cell Therapeutics management team in years:

1.2
Average Tenure
51
Average Age
  • The average tenure for the Lineage Cell Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Brian Culley

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
48
TENURE
0.9 yrs

Brandi Roberts

TITLE
Chief Financial Officer
AGE
45
TENURE
0.6 yrs

Ioana Hone

TITLE
Director of Investor Relations

Chase Leavitt

TITLE
General Counsel & Corporate Secretary
AGE
37
TENURE
0.3 yrs

Jim Knight

TITLE
Senior VP & Head of Corporate Development
TENURE
2.8 yrs

François Binette

TITLE
Senior VP & Global Head of Product Development
TENURE
3.3 yrs

Gary Hogge

TITLE
Senior Vice President of Clinical & Medical Affairs
AGE
51
TENURE
1.5 yrs

Edward Wirth

TITLE
Chief Medical Officer
AGE
54
TENURE
0.4 yrs

Bill Annett

TITLE
President & CEO of OncoCyte Corporation
COMPENSATION
$655K
AGE
65

Rami Skaliter

TITLE
Chief Executive Officer of Cell Cure Neurosciences Ltd.
AGE
61
TENURE
2.2 yrs
Board of Directors Tenure

Average tenure and age of the Lineage Cell Therapeutics board of directors in years:

5.1
Average Tenure
58
Average Age
  • The tenure for the Lineage Cell Therapeutics board of directors is about average.
Board of Directors

Al Kingsley

TITLE
Chairman of the Board
COMPENSATION
$429K
AGE
76
TENURE
10.1 yrs

Brian Culley

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
48
TENURE
0.9 yrs

Neal Bradsher

TITLE
Independent Director
COMPENSATION
$94K
AGE
53
TENURE
10.1 yrs

Deborah Andrews

TITLE
Independent Director
COMPENSATION
$101K
AGE
62
TENURE
5.3 yrs

Michael Mulroy

TITLE
Independent Director
COMPENSATION
$73K
AGE
53
TENURE
4.8 yrs

Steve Farrell

TITLE
Independent Director
COMPENSATION
$105K
AGE
54
TENURE
6.4 yrs

Angus Russell

TITLE
Independent Director
COMPENSATION
$89K
AGE
63
TENURE
4.7 yrs

Don Bailey

TITLE
Director
AGE
73
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Lineage Cell Therapeutics individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Aug 19 Buy Broadwood Capital, Inc. Company 13. Aug 19 15. Aug 19 24,553 €0.90 €21,655
15. Aug 19 Buy Brian Culley Individual 13. Aug 19 13. Aug 19 10,000 €0.90 €9,024
15. Aug 19 Buy Chase Leavitt Individual 13. Aug 19 13. Aug 19 5,000 €0.91 €4,557
15. Aug 19 Buy Brandi Roberts Individual 13. Aug 19 13. Aug 19 5,000 €0.90 €4,512
13. Sep 18 Buy Deborah Andrews Individual 11. Sep 18 11. Sep 18 1,604 €2.03 €3,253
X
Management checks
We assess Lineage Cell Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Lineage Cell Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Details
Name: Lineage Cell Therapeutics, Inc.
BT3
Exchange: DB
Founded: 1990
$133,326,888
149,642,861
Website: http://www.lineagecell.com
Address: Lineage Cell Therapeutics, Inc.
2173 Salk Avenue,
Suite 200,
Carlsbad,
California, 92008,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX LCTX Common Shares NYSE MKT LLC US USD 05. Mar 1992
DB BT3 Common Shares Deutsche Boerse AG DE EUR 05. Mar 1992
TASE LCTX Common Shares The Tel-Aviv Stock Exchange IL ILS 05. Mar 1992
TASE LCTX COM NPV The Tel-Aviv Stock Exchange IL ILS 01. Aug 2019
Number of employees
Current staff
Staff numbers
78
Lineage Cell Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/24 21:10
End of day share price update: 2019/08/09 00:00
Last estimates confirmation: 2019/08/09
Last earnings filing: 2019/08/08
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.